Highest-materiality recent filing
Lantern Pharma Q2 net loss $7.1M; LP-300 PFS benefit deepens; OMAI spin-off
Q2 2026 net loss $7.1M ($0.57/share) vs $4.3M ($0.40) YoY; operating loss down 25% to $3.5M.
Lantern Pharma spins out AI platform as Open-Medicine AI, signs commercial licenses
Lantern Pharma (LTRN) creates Open-Medicine AI as a separate company to commercialize its multi-agent AI co-scientist platform.
Net loss of $3.3M ($0.30/sh) vs $4.5M ($0.42/sh) in Q1 2025, a 27% reduction.
Lantern Pharma raises $4.4M through registered direct offering; plans to spin out AI platform
Offered 2,135,923 shares at $2.06/share (or pre-funded warrants) plus unregistered warrants for equal shares.
Lantern Pharma FY2025 net loss narrows to $17.1M; cash runway into mid-2026; pipeline advances
Cash and marketable securities $10.1M as of Dec 31, 2025, down from $24.0M; expects funding needs by late Jul–mid Sep 2026.
Lantern Pharma Q3 net loss $4.2M; LP-184 Phase 1a achieves 48% clinical benefit rate
Net loss $4.2M ($0.39/shr) vs $4.5M loss in Q3 2024; cash $12.4M, runway into Q3 2026.
Q2 2025 net loss $4.33M ($0.40/share) vs $4.96M ($0.46) a year ago; cash $15.9M as of June 30, 2025.
Lantern Pharma Q1 net loss $4.5M; LP-184 Phase 1a enrollment to complete by June 2025
Cash and equivalents $19.7M as of Mar 31, 2025, down from $24.0M at Dec 31, 2024.
Lantern Pharma reports Q4 2024 net loss $5.9M ($0.54/share); cash $24M as pipeline advances
Net loss for Q4 2024 was $5.9M ($0.54 per share) vs $4.2M ($0.39) in Q4 2023; full year net loss $1.93/share vs $1.47.
Lantern Pharma Q3 net loss $4.5M; LP-300 shows 86% clinical benefit rate in lead-in
Net loss of $4.5M ($0.42/share) vs $3.2M ($0.29/share) in Q3 2023; cash & securities $28.1M.
Lantern Pharma Q2 net loss $4.96M; LP-300 Harmonic trial 86% CBR
Net loss of $4.96M ($0.46/shr) for Q2 2024 vs $4.75M ($0.44/shr) a year ago; cash $33.3M at June 30.
Lantern Pharma reports Q4 2023 net loss $4.2M; cash $41.3M; clinical programs advance
Net loss Q4 2023 $4.2M ($0.39/sh) vs $3.4M ($0.31/sh) Q4 2022; full-year loss $1.47/sh.
Net loss $3.2M ($0.29/shr) vs $2.3M ($0.21/shr) in Q3 2022; R&D rose to $2.2M from $0.7M due to prior-year one-time payment.
Lantern Pharma Q2 2023 net loss $4.7M; cash $48.0M; LP-184 IND cleared, LP-284 IND imminent
Cash and equivalents $48.0M at June 30, 2023 ($55.2M at Dec 2022); cash runway into 2025.
Lantern Pharma Q1 net loss $3.9M; cash $51.5M; first patient dosed in Phase 2 Harmonic trial
Cash, cash equivalents, and marketable securities $51.5M as of March 31, 2023; cash runway into 2025.
Lantern Pharma Q2 net loss $4.5M; launches Phase 2 Harmonic trial for LP-300 in never-smoker NSCLC
Net loss of $4.5M ($0.41 per share) vs $2.3M ($0.21) in Q2 2021; R&D spend increased to $3.0M from $1.2M.
Lantern Pharma Q1 net loss $4.1M; cash $65.2M, RADR platform tops 20B data points
Cash and marketable securities $65.2M at March 31, 2022 vs $70.7M at Dec 31, 2021; net cash used $5.3M in Q1.
Lantern Pharma reports FY2021 net loss $12.4M; cash $70.7M; RADR platform surpasses 18B data points
Cash and marketable securities $70.7M at Dec 31, 2021, up from $19.2M at year-end 2020; share repurchase authorized up to $7M.
Lantern Pharma receives Rare Pediatric Disease and Orphan Drug designations for LP-184 in ATRT
FDA grants Rare Pediatric Disease Designation and Orphan Drug Designation for LP-184 to treat atypical teratoid rhabdoid tumor (ATRT).
Lantern Pharma Q3 net loss $4.05M, cash $73.8M; RADR hits 10B datapoints, LP-184 ODD
Net loss $4.05M ($0.36 per share) vs $1.70M in Q3 2020; R&D expenses $2.96M up from $0.60M.
Lantern Pharma reports Q2 2021 net loss $2.3M; cash $79.6M; positive LP-184 pancreatic data
Net loss $2.3M ($0.21/sh) vs $833K ($0.31/sh) in Q2 2020; R&D expenses rose to $1.16M.
On April 20, 2022, Leslie W. Kreis, Jr. notified Lantern Pharma Inc. (the “Company”) that he will not stand for reelection to the Company’s Board of Directors.
Max materiality 0.80 · Median 0.55 · Most common event earnings